Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS
United Therapeutics Corporation logo

United Therapeutics Corporation

Sector: Healthcare   

Industry: Biotechnology

227.28
 
USD
  
0.53
  
(0.23%)
Optionable: Yes  Market Cap: 10,671 M  90-day average vol: 362,015

Previous close: 226.75  Open: 226.7  Bid: 209.17  Ask: 233.9
52 week range    
204.44   
   261.54
Peers   
LLY / 
GILD / 
TEVA / 
PFE / 
BAX / 
CYTK / 
GSK / 
Last updated: Thursday 29th February 2024
62
MarketXLS Rank
60
Value
61
Technical
65
Quality

Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS

Get started today
Search for a stock

🎉 Exciting news! 🎉

You are invited to join our Discord Channel.

Interact, learn, and grow with experts in the markets!

Join our Discord

Metrics

Peers

StockDividendMarket Cap (B)PEPrice ($)

BAX

0.012943 B35.986.87

CAH

0.037314 B13.352.63

CYTK

3 B-10.734.95

GILD

0.044486 B11.763.76

GSK

LLY

0.0161238 B37.4243.55

PFE

0.0302298 B15.153.21

TEVA

Financials

UTHR Income Statement

Annual
Dec-13Dec-14Dec-15Dec-16Dec-17Dec-18Dec-19Dec-20Dec-21Dec-22
Amortization of intangibles-3 M-1 M-1 M-600000.0-500000.0-100000.0-200000.0-200000.0-100000.0-100000.0
Basic EPS from continuing operations3.49
Basic EPS total3.497.0614.1716.299.513.54-2.3911.6510.615.98
Basic weighted shares outstanding50 M48 M46 M44 M44 M44 M44 M44 M45 M46 M
Cost of sales-131 M-126 M-69 M-73 M-106 M-199 M-118 M-108 M-122 M-152 M
Depreciation-29 M-31 M-32 M-31 M-30 M-36 M-46 M-50 M-50 M-51 M
DepreciationAndAmortization-29 M-31 M-32 M-31 M-30 M-36 M-46 M-50 M-50 M-51 M
Diluted EPS total3.286.2812.7215.259.3113.39-2.3911.5410.0615.0
Diluted normalized net income/share3.28
Diluted weighted shares outstanding53 M54 M51 M47 M45 M44 M44 M45 M47 M49 M
GainOnSaleOfPPE350 M
GainOnSaleOfSecurity-50 M3 M93 M900000.0
GeneralAndAdministrativeExpense-3 M-4 M-4 M-4 M-5 M-4 M-5 M-3 M-4 M-5 M
Gross operating profit986 M1,163 M1,397 M1,526 M1,620 M1,163 M995 M951 M1,096 M1,303 M
ImpairmentOfCapitalAssets-17 M-5 M-19 M-11 M
Income before tax279 M525 M1,044 M1,060 M770 M759 M-165 M639 M594 M951 M
Income restructuring and M&A-54 M-36 M
Income taxes104 M185 M393 M347 M352 M170 M-60 M124 M118 M223 M
Interest income4 M-39 M-25 M44 M29 M17 M45 M
InterestExpenseNonOperating18 M18 M5 M4 M9 M14 M44 M24 M19 M32 M
InterestExpenseOperating-18 M-18 M-5 M
MiscOtherSpecialCharges4 M4 M100000.02 M2 M-8 M23 M49 M42 M-40 M
Net income from total operations175 M340 M652 M714 M418 M589 M-104 M515 M476 M727 M
NetIncomeCommonStockholders175 M340 M652 M714 M418 M589 M-104 M515 M476 M727 M
NetIncomeContinuousOperations175 M340 M652 M714 M418 M589 M-104 M515 M476 M727 M
NetNonOperatingInterestIncomeExpense-18 M-18 M-5 M-4 M-48 M-39 M5 M-2 M13 M
Operating income292 M539 M699 M1,062 M815 M805 M-188 M594 M556 M980 M
Operating income before depreciation (EBITDA)327 M575 M1,085 M1,096 M810 M809 M-75 M712 M662 M1,034 M
OperatingExpense693 M624 M698 M464 M805 M358 M1,183 M358 M540 M323 M
Other income net-4 M-4 M-350 M-2 M-2 M8 M-23 M-40 M-40 M42 M
Other special charges-58 M
OtherGandA-3 M-4 M-4 M-4 M-5 M-4 M-5 M-3 M-4 M-5 M
OtherImpairmentOfCapitalAssets9 M2 M2 M
OtherOperatingExpenses210 M-700000.0-6 M-20 M
RentAndLandingFees-3 M-4 M-4 M-4 M-5 M-4 M-5 M
Research & development expense299 M243 M245 M148 M265 M358 M1,183 M358 M540 M323 M
ResearchExpense299 M243 M245 M148 M265 M358 M1,183 M358 M540 M323 M
RestructringAndMnAIncome-54 M-36 M
Revenue per share-3 M-1 M-1 M-600000.0-500000.0-100000.0-200000.0-200000.0-100000.0-100000.0
SalariesAndWages-321 M-190 M-280 M-12 M-73 M-700000.0-45 M-164 M-138 M-107 M
Selling Gen & administrative expense394 M381 M453 M317 M330 M266 M
SellingAndMarketingExpense394 M381 M453 M317 M330 M266 M
SellingExpense394 M381 M453 M317 M330 M266 M
Special income/charges54 M36 M17 M5 M19 M11 M
Total Income available for interest expense (EBIT)279 M525 M1,044 M1,064 M779 M773 M-121 M662 M613 M983 M
Total common shares outstanding50 M47 M45 M45 M43 M44 M44 M45 M45 M46 M
Total net income175 M340 M652 M714 M418 M589 M-104 M515 M476 M727 M
Total ordinary shares47 M47 M47 M47 M47 M47 M47 M47 M47 M47 M
Total revenues1,117 M1,289 M1,466 M1,599 M1,725 M1,628 M1,449 M1,483 M1,686 M1,936 M
TotalExpenses562 M498 M629 M392 M699 M159 M1,065 M250 M418 M171 M
TotalRevenue1,107 M1,280 M1,461 M1,599 M1,725 M1,628 M1,449 M1,483 M1,686 M1,936 M
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.

We respect your privacy and will never share your email.
MarketXLS is a complete Excel stock solution

Kevin Hsu

StockKevin.com

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel

Lloyd Lenase

Option Day Trader

MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.

Dave

Swing trader since 2011

I like to access historical closing prices on a particular date. That makes tracking performance easy.

Patrick Cusatis, Ph.D., CFA

Associate Professor of Finance - Penn State University